Rodman & Renshaw analyst Michael King Jr. initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $17.00.

The analyst comments "We are initiating coverage of BioXcel Therapeutics with a BUY rating and $17 price target based on the company’s differentiated at-home agitation franchise, expanding BXCL501 neuropsychiatry optionality, and an extreme disconnect between enterprise value and risk-adjusted cash flow potential. The core thesis centers on label expansion for IGALMI (dexmedetomidine sublingual film) from supervised settings into the much larger at-home market for acute agitation in bipolar disorder and schizophrenia. This expansion is supported by positive SERENITY At-Home Phase 3 data and a purpose-built correlation study that together substantially de-risk the regulatory path for an sNDA that was filed with the FDA on January 14, 2026, and a potential approval during late 2H26, assuming standard approval timelines. In addition, on March 5, 2026, BioXcel announced positive Phase 2 topline results for BXCL501 in opioid withdrawal, with BXCL501 240 µg twice daily achieving greater than 30% reduction in SOWS‑Gossop scores and numerically outperforming lofexidine 0.54 mg four times daily, further validating the molecule’s anxiolytic and autonomic‑modulating profile in a high‑need population. These results incrementally strengthen the long‑term lifecycle‑expansion and indication‑broadening narrative around BXCL501. The company has also augmented its balance sheet with a recent ~$8.0 million registered direct offering of common stock and accompanying warrants that closed on March 11, 2026, modestly extending the cash runway ahead of the at‑home IGALMI regulatory decision. Trading at approximately a $36 million market capitalization, we think BioXcel offers investors an option-like valuation for an asset that already carries FDA approval in supervised care and now has validating data in the home environment."

For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.

Shares of BioXcel Therapeutics closed at $1.54 yesterday.